Compare · A vs ALMR
A vs ALMR
Side-by-side comparison of Agilent Technologies Inc. (A) and Alamar Biosciences Inc. (ALMR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both A and ALMR operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- A is the larger of the two at $49.49B, about 26.0x ALMR ($1.90B).
- ALMR has been more active in the news (7 items in the past 4 weeks vs 6 for A).
- A has more recent analyst coverage (25 ratings vs 5 for ALMR).
- Company
- Agilent Technologies Inc.
- Alamar Biosciences Inc.
- Price
- -
- -
- Market cap
- $49.49B
- $1.90B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1999
- 2026
- News (4w)
- 6
- 7
- Recent ratings
- 25
- 5
Agilent Technologies Inc.
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid and gas chromatography systems and components; liquid and gas chromatography mass spectrometry systems; inductively coupled plasma mass and optical emission spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate readers; laboratory software, information management, and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression profiling, as well as sequencing target enrichment, genetic data management, and interpretation support software; and equipment to produce synthesized oligonucleotide. It also offers immunohistochemistry, in situ hybridization, and hematoxylin and eosin staining and special staining; instruments, consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. It has collaboration agreement with SGS AXYS. The company was incorporated in 1999 and is headquartered in Santa Clara, California.
Latest A
- Agilent to Acquire Proscia, Advancing AI-Enabled Digital Pathology and Scientific Intelligence
- Agilent Introduces the NovoStation Sample Preparation System for Automated Flow Cytometry Workflows
- Agilent Introduces Gen5 AI Cell Identification Module for BioTek Automated Cell Imagers
- SEC Form EFFECT filed by Agilent Technologies Inc.
- SEC Form 424B3 filed by Agilent Technologies Inc.
- Agilent Launches TapeStationDx Systems for Clinical NGS Sample Quality Control
- CORRECTING and REPLACING Agilent Announces Cash Dividend of 25.5 Cents per Share
- Agilent Announces Cash Dividend of 25.5 Cents per Share
- Agilent to Participate in J.P. Morgan U.S. All Stars Conference
- Director Boehnlein Glenn S was granted 817 shares (SEC Form 4)
Latest ALMR
- SEC Form 144 filed by Alamar Biosciences Inc.
- SEC Form 144 filed by Alamar Biosciences Inc.
- SEC Form 144 filed by Alamar Biosciences Inc.
- SEC Form 144 filed by Alamar Biosciences Inc.
- Alamar Biosciences to Report Third Quarter 2026 Financial Results on November 3, 2026
- Alamar Biosciences Names Former Grail CEO Bob Ragusa to Board of Directors and Expands Leadership Team
- Lancet Neurology Study Using Alamar Biosciences’ Technology Reveals Divergent Biological Responses to Alzheimer’s Treatment
- General Counsel Brottem John L. was granted 29,000 shares (SEC Form 4)
- SEC Form 3 filed by new insider Brottem John L.
- Director Ragusa Robert P was granted 5,686 shares (SEC Form 4)